Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside...
November 05, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell...
October 30, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...
October 29, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant...
October 14, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data...
September 23, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem...
August 27, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C....
August 06, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant...
July 22, 2025 07:01 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...
July 22, 2025 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Announces Leadership Transition

Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple...